However, after more than 50 years of intensive research and development, only one malaria vaccine candidate, RTS,S (Mosquirix®), based on the central repeat and C‐terminal epitopes of the major sporozoite surface antigen, circumsporozoite protein (CSP), have completed phase‐3 trials. The gene discussed is DNAJC5; the disease is malaria.